© 2022 MJH Life Sciences and Drug Topics. All rights reserved.
© 2022 MJH Life Sciences™ and Drug Topics. All rights reserved.
June 15, 2022
Infliximab biosimilars have been available since 2016.
June 03, 2022
The average sales price (ASP) for biosimilars of Neupogen has declined more than 50% since these lower cost agents began to be sold in 2015.
June 01, 2022
Pharmacy benefit managers can help health plans understand when to best leverage and align to biosimilars and other cost-effective treatments.
May 19, 2022
Circle 2023 on your calendar. That's when as many as 11 biosimilars to Humira are headed for the US market.
May 13, 2022
Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
March 19, 2022
Gaps exist in knowledge about interchangeability and substitutions.
February 22, 2022
A new report by Cardinal Health includes research findings on insulin biosimilars use among retail pharmacists and physicians.
February 02, 2022
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Thomas C. Blevins, MD, ECNU, FACE, FNLA, review FDA-approved basal insulins for the management of diabetes.
Experts in diabetes management discuss data from key clinical trials—INSTRIDE 1, INSTRIDE 2, and INSTRIDE 3—and evaluate the use of insulin glargine-yfgn as an interchangeable product with biologics.
Thomas C. Blevins, MD, ECNU, FACE, FNLA, provides an overview of biosimilars and discusses interchangeability status among biosimilars such as for insulin glargine-yfgn for the management of diabetes.